Source-linked briefing Health

Soligenix’s SGX945 Wins European Orphan Drug Designation

Soligenix’s SGX945 Wins European Orphan Drug Designation

Soligenix received orphan designation from the European Commission for SGX945. The status bolsters its pipeline and may provide regulatory incentives to aid development.

Original headline

Soligenix Inc. (NASDAQ: SNGX) Strengthens Pipeline As European Commission Grants SGX945 Orphan Status